Related Experiment Video
Updated: Jul 14, 2025
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.2K
Outcomes and Medical Therapy in Myocardial Infarction With Nonobstructive Coronary Arteries: A Systematic Review and
Michael Tao1, Mohammed Al-Sadawi2, Simrat Dhaliwal1
1Division of Cardiology, Department of Medicine, Stony Brook University Hospital, Stony Brook, New York.
The American Journal of Cardiology
|October 6, 2023
Summary
Patients with myocardial infarction with nonobstructive coronary arteries (MINOCA) face lower adverse outcomes than those with coronary artery disease. Standard medical therapy offers no significant reduction in major adverse cardiovascular events for MINOCA patients.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Myocardial infarction with nonobstructive coronary arteries (MINOCA) remains poorly understood, with unclear clinical and therapeutic implications.
- The effectiveness of medical therapies in mitigating cardiovascular risks for MINOCA patients requires further assessment.
Approach:
- A comprehensive meta-analysis was performed, comparing adverse cardiovascular outcomes in MINOCA versus myocardial infarction with coronary artery disease (MICAD).
- The efficacy of medical therapy in reducing adverse outcomes within the MINOCA population was also evaluated.
- Data from 29 studies (893,134 participants) for MINOCA vs. MICAD and 9 studies (27,731 participants) for medical therapy efficacy were synthesized.
Key Points:
- MINOCA patients demonstrated a significantly lower risk of adverse cardiovascular outcomes compared to MICAD patients.
- Medical therapy did not significantly reduce the risk of major adverse cardiovascular events (MACE) in MINOCA patients.
- A trend towards reduced risk was observed with beta-blocker treatment in MINOCA patients.
Conclusions:
- MINOCA is associated with a lower risk of both in-hospital and long-term adverse outcomes relative to MICAD.
- Current standard medical therapy does not significantly lower the risk of adverse cardiovascular outcomes in MINOCA.
- Further high-quality research is essential to determine the efficacy of specific medication classes for MINOCA etiologies.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
01:26Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
01:29Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
01:20Angina V: Nursing Management
18
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
18